|
[1]
|
Farel CE, Dennis AM. Why everyone (almost) with HIV needs to be on treatment: a review of the critical data. Infect Dis Clin North Am 2019;33(3):663 − 79. http://dx.doi.org/10.1016/j.idc.2019.05.002CrossRef
|
|
[2]
|
Maina EK, Bonney EY, Bukusi EA, Sedegah M, Lartey M, Ampofo WK. CD4+ T cell counts in initiation of antiretroviral therapy in HIV infected asymptomatic individuals; controversies and inconsistencies. Immunol Lett 2015;168(2):279 − 84. http://dx.doi.org/10.1016/j.imlet.2015.10.005CrossRef
|
|
[3]
|
Ejigu Y, Magnus JH, Sundby J, Magnus M. Health outcomes of asymptomatic HIV-infected pregnant women initiating antiretroviral therapy at different baseline CD4 counts in ethiopia. Int J Infect Dis 2019;82:89 − 95. http://dx.doi.org/10.1016/j.ijid.2019.02.019CrossRef
|
|
[4]
|
The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015;373(9):795 − 807. http://dx.doi.org/10.1056/NEJMoa1506816CrossRef
|
|
[5]
|
Esber AL, Coakley P, Ake JA, Bahemana E, Adamu Y, Kiweewa F, et al. Decreasing time to antiretroviral therapy initiation after HIV diagnosis in a clinic-based observational cohort study in four African countries. J Int AIDS Soc 2020;23(2):e25446. http://dx.doi.org/10.1002/jia2.25446CrossRef
|
|
[6]
|
Medland NA, Chow EPF, McMahon JH, Elliott JH, Hoy JF, Fairley CK. Time from HIV diagnosis to commencement of antiretroviral therapy as an indicator to supplement the HIV cascade: dramatic fall from 2011 to 2015. PLoS One 2017;12(5):e0177634. http://dx.doi.org/10.1371/journal.pone.0177634CrossRef
|
|
[7]
|
Lee JS, Humes EA, Hogan BC, Buchacz K, Eron Jr JJ, Gill MJ, et al. CD4 count at entry into care and at antiretroviral therapy prescription among adults with human immunodeficiency virus in the United States, 2005-2018. Clin Infect Dis 2021;73(7):e2334 − 7. http://dx.doi.org/10.1093/cid/ciaa1904CrossRef
|
|
[8]
|
Xu JF, Sönnerborg A, Gao LM, Wang PC, Bouey JZH, Cheng F. Delayed treatment for people living with HIV in China, 2004-2016: an analysis of an observational cohort. Int J Environ Res Public Health 2020;17(5):1809. http://dx.doi.org/10.3390/ijerph17051809CrossRef
|
|
[9]
|
Lourenço L, Samji H, Nohpal A, Chau W, Colley G, Lepik K, et al. Declines in highly active antiretroviral therapy initiation at CD4 cell counts ≤ 200 cells/μL and the contribution of diagnosis of HIV at CD4 cell counts ≤ 200 cells/μL in British Columbia, Canada. HIV Med 2015;16(6):337 − 45. http://dx.doi.org/10.1111/hiv.12212CrossRef
|
|
[10]
|
Zhang XQ. Anti-retroviral drugs: current state and development in the next decade. Acta Pharm Sin B 2018;8(2):131 − 6. http://dx.doi.org/10.1016/j.apsb.2018.01.012CrossRef
|